Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

BACKGROUND: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR(+)) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Shinzaburo, Masuda, Norikazu, Iwata, Hiroji, Mukai, Hirofumi, Horiguchi, Jun, Puttawibul, Puttisak, Srimuninnimit, Vichien, Tokuda, Yutaka, Kuroi, Katsumasa, Iwase, Hirotaka, Inaji, Hideo, Ohsumi, Shozo, Noh, Woo-Chul, Nakayama, Takahiro, Ohno, Shinji, Rai, Yoshiaki, Park, Byeong-Woo, Panneerselvam, Ashok, El-Hashimy, Mona, Taran, Tetiana, Sahmoud, Tarek, Ito, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210660/
https://www.ncbi.nlm.nih.gov/pubmed/23404211
http://dx.doi.org/10.1007/s12282-013-0444-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210660/
https://www.ncbi.nlm.nih.gov/pubmed/23404211
http://dx.doi.org/10.1007/s12282-013-0444-8

Ejemplares similares